The outcry was as loud as it was immediate. On Oct 18, the Court of Justice at the European Union (CJEU) in Luxembourg ruled that all processes that necessitate the prior destruction of human embryos or their use as base material, with the exception of processes that can be applied for the benefit of the embryo itself, are excluded from patent protection. And the European stem cell community erupted in a chorus of dismay.
展开▼
